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SchizophreniaAbstract Objective: The present study was carried out to investigate and compare the three meth-
ods for calculating total antipsychotic dose among outpatients with schizophrenia attending pri-
mary psychiatric health care centers. The three methods were: Deﬁned Daily Doses (DDDs),
chlorpromazine equivalents (CPZeq) and percentages of the British National Formulary (BNF)
maximum.
Methodology: Antipsychotic drug dosing data for 250 patients with schizophrenia were investi-
gated by calculating Spearman’s rank correlation coefﬁcients. Factors associated with antipsychotic
dose, expressed as DDDs, CPZeq and percentages of the BNF maximum recommended daily dose,
were investigated by means of linear regression analysis.
Results: Spearman’s correlation showed that there is a signiﬁcant relationship between all pairs
of the three dosing methods. In all three methods, coherence was strongest when dealing with ﬁrst
generation antipsychotics (FGA). Linear regression analyses showed a high degree of coherence
128 W.M. Sweileh et al.between antipsychotic doses expressed as DDDs, CPZeq and percentages of the BNF maximum
recommended daily dose.
Conclusion: All three testedmethods are reliable and coherent for calculating antipsychotic dosing.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Drug utilization studies are important in detecting drug
related-problems and in assessing conformance of clinical
practice to international recommendations. Such studies are
not meant to ﬁnd blame, but to implement regulations, and
cost-effective treatment protocols. Schizophrenia is a devastat-
ing mental illness that affects around 0.3–0.7% of people at
some point in their life, or 24 million people worldwide as in
the World Health Organization (WHO) report 2011 (WHO,
2011). The introduction of chlorpromazine to clinical use in
early 1950s and subsequent antipsychotic agents have revolu-
tionized the treatment of schizophrenia and has led to an in-
crease in prescribing of this category of drugs for various
mental disorders. The interest in antipsychotic agents stimu-
lated researchers in several countries to publish data regarding
antipsychotic drug utilization (Alonso et al., 2004; Piparva
et al., 2011). Such studies focus not only on the pattern of anti-
psychotic prescribing but also on the appropriateness of anti-
psychotic dose which is mentioned in international guidelines
(Buchanan et al., 2009; NICE, 2011). Calculation of the dose
of antipsychotic agents has been a subject for debate. The three
methods suggested to calculate the antipsychotic dose are:
Chlorpromazine equivalents (CPZeq), percentage of British
National Formulary (BNF) maximum, and Deﬁned Daily
Dose (DDD) (Nose et al., 2008). Few studies have been carried
out to investigate the coherence between these methods. A
study by Nose et al. showed a high degree of coherence be-
tween antipsychotic doses expressed as DDDs, CPZeq and
percentage of BNF maximum recommended daily dose and
that the DDD system is a reliable tool for standardizing anti-
psychotic doses in drug utilization research (Nose et al., 2008).
However Rijcken et al. found a great discrepancy between
CPZeq and DDD methods of comparing antipsychotic drug
doses and recommended further research in this regard
(Rijcken et al., 2003).
Studies comparing the various methods for calculation of
antipsychotic dosing are few. Therefore, this study was carried
out to further investigate and compare the three methods for
calculating total antipsychotic dose among outpatients with
schizophrenia attending primary psychiatric health care
centers.
2. Methods
The data for the present study were based on a cross sectional
study conducted between August 2011 and February 2012 to
investigate the prescribing pattern of antipsychotics in primary
healthcare centers in northern West-Bank, Palestine. The Pal-
estinian territories, where the study took place, comprise the
West Bank, Gaza Strip and East Jerusalem. This study was
carried out at four governmental primary psychiatric health-
care centers located in Nablus, Tulkaram, Jenin and Qalqilia
in northern West-Bank, Palestine. Patients who fulﬁlled thefollowing criteria were considered for the study: (1) their age
was above 16 years, (2) they were diagnosed with schizophre-
nia as deﬁned by Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV), (3) they had not been suffering from an
acute attack of psychiatric illness during the past year, and (4)
their drug regimen had not been changed in the past 6 months
as evident from their medical ﬁles. Patients who had the fol-
lowing characteristics were excluded from the study: (1) newly
diagnosed patients and (2) patients who were not on any anti-
psychotic medication. The ﬁnal sample collected during the
study period was 250 patients. We developed data collection
forms that covered the following areas: socio-demographic
variables, psychiatric history, antipsychotic medication cur-
rently being used, and history of psychiatric hospitalization.
Focus group discussions were continuously held between the
research team to maintain rationale of the data collection pro-
cess. Regular evaluations took place throughout the abstrac-
tion period to identify any problems in the data collection,
the interpretation of deﬁnitions, and the application of study
criteria. Before commencing data analysis, an extensive series
of checks were performed for data consistency, proper
sequences of data, and an evaluation of missing or incomplete
data. The data collection form was modiﬁed by the principle
researchers and the modiﬁed version was reviewed by experts
to ensure content and construct validity. Data from the
pre-test evaluation were not included in the ﬁnal analysis.
Approval to perform the study was obtained from the Palestin-
ian Ministry of Health, the College of Graduate Studies at An-
Najah National University and the Institutional Review
Boards (IRB) committee at An-Najah National University.
2.1. Tested variables
2.1.1. Chlorpromazine dose equivalents (CPZeq)
The CPZeq is a measure of the relative antipsychotic potencies
of neuroleptics. They are generally expressed as a ratio, relative
to the arbitrary value of 1, which corresponds to the antipsy-
chotic effects of chlorpromazine. The daily dose of antipsy-
chotic medication prescribed to each patient was converted
into milligram equivalents of chlorpromazine according to con-
version factors derived from the literature (Davis, 1976; Rey
et al., 1989; Woods, 2003; Xiang et al., 2008; Joseph et al.,
2011). Total CPZeq was constructed by calculating a total daily
dose of each antipsychotic listed in the medical ﬁle. Then each
converted antipsychotic-speciﬁc CPZeq amount is added to ar-
rive at a total dose. This CPZ equivalency is most often based
on the antidopaminergic action and in general does not take
into account the inﬂuence of antipsychotics on serotonergic,
histaminergic, cholinergic, and adrenergic receptors. Generally,
CPZ-equivalent values per drug are ambiguous in the literature
(Rey et al., 1989). The origin of the used equivalency value per
study is in general quite opaque. Most likely, researchers base
their equivalencies on pharmacologic drug registration studies
and other available literature. As a result of this nontransparency,
Table 1 Antipsychotic medications encountered in the study.
Antipsychotic medications
Medication N (%)
Chlorpromazine tablet 128 (31.5)
Fluphenazine depot 125 (30.8)
Haloperidol tablet 74 (18.3)
Clozapine tablet 35 (8.6)
Olanzapine tablet 15 (3.7)
Haloperidol depot 11 (2.7)
Risperidone tablet 8 (2.0)
Triﬂuoperazine tablet 7 (1.7)
Zuclopenthixol depot 2 (0.5)
Thioridazine tablet 1 (0.2)
Total 406 (100)
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reported in the literature. For example, the CPZ-equivalent for
haloperidol varies from 40 to 60 times more potent than CPZ
(Rey et al., 1989). The ambiguity in CPZeq becomes more
important when dealing with second generation antipsychotics
(SGA) because there are evidence that the maximum efﬁcacy of
this drug class occurs at 70–80% of the dopamine receptor
occupancy and these levels can be achieved at doses much lower
than have been previously thought necessary (McEvoy et al.,
1991; Stone et al., 1995).
2.1.2. Percentage of BNF maximum
To calculate a total daily prescribed antipsychotic dose as a
percentage of the maximum BNF dose, we determined the per-
centage of BNF maximum dosage for each antipsychotic that
is used, and then we summed the percentages (Yorston, 2000).
For example, for a person prescribed clozapine 400 mg a day
and oral haloperidol 5 mg three times a day, the respective per-
centages would be 44% and 50%, giving a total antipsychotic
prescribed dosage of 94% of the BNF maximum. The BNF is
updated twice a year and maximum doses are assumingly accu-
rate and are generally based on toxicity rather than efﬁcacy
(Yorston, 2000).
2.1.3. Deﬁned Daily Dose (DDD)
The DDD is a theoretical unit of measurement deﬁned as the
assumed average maintenance daily dose for a drug, used for
its main indication in adults (WHO, 2010). The DDD for anti-
psychotic agents is calculated by converting the daily doses in
milligrams into multiples of the DDD by dividing the pre-
scribed daily dose (PDD) by the DDD (PDD/DDD) (WHO,
2010). For patients who were on multiple antipsychotics, the
total DDD was calculated by adding the DDD for each anti-
psychotic agent in a way similar to that mentioned for percent-
age BNF maximum.
2.2. High doses
For the purpose of this study, patients receiving percentage of
BNF maximum dose >100% were considered to have a high
dose. On the other hand, patients who were receiving >600
CPZeq were considered to have a high dose. This upper limit
of CPZeq was based on international recommendations for
maintenance dose between 300 and 600 CPZeq (Buchanan
et al., 2009). For DDDs, no deﬁnition of high dose is available
in the literature and therefore was dealt with as a continuous
variable.
2.3. Data analysis
Descriptive statistics for all study variables were computed.
These descriptive statistics included frequencies and percent-
ages for all categorical variables in addition to means, stan-
dard deviations and ranges for all normally distributed
continuous variables while median and inter quartile range
(Q1–Q3) for continuous variables that were not normally dis-
tributed. Variables were tested for normality using the Kol-
mogorov–Smirnov test. Correlation between variables was
tested using the Spearman Rho correlation test. The conven-
tional 5% signiﬁcance level was used throughout the study.Linear regression was carried out to analyze the association
between each method and various independent variables. All
statistical analyses were conducted using Statistical Package
for Social Sciences SPSS (PASW version 18.0; IBM, Somers,
NY) statistical packages for Windows.
3. Results
3.1. General descriptive statistics of the study sample
Antipsychotic medications for 250 patients were studied and
analyzed. Gender distribution of the patients was: 68 (27.2%)
females and 182 (72.8%) males. The mean age of the patients
was 41.9 ± 11.8 years. The median duration of illness was 15
(Q1–Q3: 9–20) years. The median number of psychiatric hospi-
talization of the patients during their lifetime was 1 (Q1–Q3: 0–
2). The total number of antipsychotic drugs used was 406 with a
mean of 1.6 ± 0.7 (95% CI: 1.5–1.7) per patient. The antipsy-
chotics were mainly from the ﬁrst-generation antipsychotic
(FGA) type (348, 85.7%) and the remaining were from the sec-
ond generation antipsychotics (SGA). Table 1 shows the types
of antipsychotic medications encountered in the study. One
hundred and twenty-four clients (49.6%) were using antipsy-
chotic monotherapy while 126 (50.4%) clients were using anti-
psychotic combination. The most common combination was
‘‘FGA+ FGA’’ (78; 61.9%) followed by ‘‘FGA+ FGA+ F-
GA’’ (24; 19%) and ‘‘FGA+ SGA’’ (17; 13.5%).
3.2. Correlation between DDD, CPZeq and percentage of BNF
maximum
Table 2 shows a list of antipsychotic medications encountered
in the study and the corresponding CPZeq, %BNF max and
DDD for each medication. The relationship between the three
methods is shown in Table 3. The Spearman Rho correlation
between DDDs and CPZeq was 0.92 (p< 0.01), between
DDDs and percentage of BNF maximum dose was 0.82
(p< 0.01) and ﬁnally between percentage of BNF maximum
dose and CPZeq was 0.85 (p> 0.01).
Linear regression of that the factors associated with
antipsychotic dosages expressed as DDDs, CPZEq and
percentages of the BNF maximum recommended daily dose re-
vealed a positive association between antipsychotic combina-
tion and duration of psychiatric illness in all three models.
Table 2 Antipsychotic dosing equivalents.
Medication CPZ equivalent dose to 100 mg CPZa 100% BNF maxb DDD (mg)c
Chlorpromazine tablet 100 1000 300
Haloperidol tablet 2 30 8
Triﬂuoperazine tablet 5 50 20
Thioridazine tablet 100 150 300
Fluphenazine decanoate 13/4 weeks 50 1
Haloperidol decanoate 40/4 weeks 18 3.3
Clozapine tablet 100 900 300
Olanzapine tablet 4 20 10
Risperidone tablet 2 16 5
Quetiapine tablet 75 750 400
a Data obtained from Woods (2003); Xiang et al. (2007); Xiang et al. (2008); Buchanan et al. (2009).
b Joint Formulary Committee and Pharmaceutical Society of Great Britain (2010).
c WHO (2010).
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with antipsychotic dose only when doses were expressed as
CPZeq, whereas in the other two models the association was
not signiﬁcant (Table 4).
The impact of the type of antipsychotic regimen (FGA,
SGA and FGA+ SGA) on the regression line among the dif-
ferent dosing methods was investigated. The highest r square
value was seen with the regression line for the FGA while that
for SGA was highest for regression line between CPZeq and
percentage of BNF maximum (Table 5).
According to the deﬁnition of high dose, 61 (24.4%) pa-
tients were receiving high antipsychotic dose measured using
percentage of BNF maximum dose while there were 57
(22.8%) patients receiving high dose measured using CPZeq.
In both methods, the depot antipsychotic medications as ﬂu-
phenazine or haloperidol were associated with high dose
regimens.
3.3. Antipsychotic combination and antipsychotic dose
Patients on antipsychotic combination had a mean CPZeq of
614.3 ± 267.1 (95% CI: 567.2–661.4 mg) while those on
monotherapy had a mean CPZeq of 256.6 ± 127.5 (95% CI
233.9–279.3 mg) (p< 0.01). Categorization of CPZeq dose
showed that 88 (35.2%) patients were using sub-therapeutic
doses (<300 mg CPZeq), 105 (42.2%) were using optimum
dose (300–600 mg CPZeq) and 57 (22.8%) were using supraTable 3 Correlation between DDDs, %BNF max and CPZeq.
Method
%BNF max Correlation Coeﬃcient
Sig. (2-tailed)
N
DDDs Correlation Coeﬃcient
Sig. (2-tailed)
N
CPZeq Correlation Coeﬃcient
Sig. (2-tailed)
N
** Signiﬁcant difference (p-Value < 0.05).therapeutic doses (>600 mg CPZeq). Only 7 (2.8%) clients
were using supra-maximal dose (CPZeq > 1000 mg). Patients
on antipsychotic combination had a mean%BNF maximum
dose of 105.4 ± 48.3 (95% CI: 96.9–114) while those on
monotherapy had a mean %BNF maximum dose of
44.4 ± 33.8 (95% CI: 38.4–50.4) (p< 0.01).
4. Discussion
The present study endorses the ﬁndings that there is coherence
between DDDs, CPZeq and percentage of BNF maximum
dose methods and all are reliable tools for standardizing anti-
psychotic doses in drug-utilization research. Our ﬁndings are
in agreement and further endorse the ﬁndings of (Nose et al.,
2008). The agreement in the type of antipsychotic drugs that
were associated with high dose using either percentage of
BNF maximum dose or CPZeq methods endorses the ﬁndings
of Yortson who showed that both CPZeq and percentage of
BNF maximum dose showed similar accuracy in ﬁnding high
doses associated with ﬂuphenazine or haloperidol depot
(Yorston, 2000).
It should be emphasized that our conclusion is valid for
outpatients who are receiving antipsychotic agents at the main-
tenance dose which is lower than that recommended for acute
psychiatric treatment. Furthermore, our study was based on
patients diagnosed with schizophrenia and were using the anti-
psychotics for this purpose. Therefore, our conclusion cannot%BNF max DDDs CPZeq
1.000 0.820** 0.853**
0.000 0.000
250 250 250
0.820** 1.000 0.917**
0.000 0.000
250 250 250
0.853** 0.917** 1.000
0.000 0.000
250 250 250
Table 4 Linear regression of the factors associated with antipsychotic dosages expressed as DDDs, CPZeq and percentages of the
BNF maximum.
Variable Sig (P)
CPZeq %BNF max DDDs
Gender 0.837 0.772 0.892
Age 0.472 0.101 0.183
Education 0.461 0.464 0.701
Married 0.693 0.787 0.584
Occupation 0.161 0.120 0.035
Waist circumference 0.023 0.097 0.404
Duration 0.038 0.000 0.029
No. of hospitalization 0.313 0.127 0.170
Monotherapy 0.000 0.000 0.000
Table 5 Impact of the type of antipsychotic regimen (FGA,
SGA and FGA+ SGA) on the regression line among the
different dosing methods.
Method Line of best ﬁt (r2)
FGA SGA FGA+ SGA
%BNF max versus CPZeq 0.74 0.61 0.32
%BNF max versus DDDs 0.70 0.28 0.20
CPZeq versus DDDs 0.90 0.38 0.54
Dose calculation methods of antipsychotics 131be extrapolated to measure the antipsychotic dose when these
drugs are used for other psychotic or mental disorders.
Early studies on antipsychotic drug utilization used CPZeq
to assess the antipsychotic dose (Peralta et al., 1994; Warner
et al., 1995). However, the CPZeq method has some draw-
backs particularly the fact that the CPZeq values vary across
literature and might not be accurate for SGA (Dewan and
Koss, 1995). Furthermore, the values for CPZeq do not under-
go annual revision after marketing the antipsychotic (Rey
et al., 1989). The CPZeq is mainly based on dopamine-2 recep-
tor activity, which is the major site of action of FGA.
However, SGA act through a complex spectrum of receptor
binding properties, which should be taken into account when
comparing antipsychotic doses. This actually might partially
explain the highest correlation between the three methods on
patients receiving FGA while the correlation was weaker when
the methods were applied to patients receiving SGA.
Although the BNF method is easy and available, it has
some inherent problems. For example, the BNF is not adopted
internationally and therefore different maximum recom-
mended doses might be found in different formularies used
by other countries. Despite this drawback, some investigators
recommended the use of the BNF method instead of the CPZ
method (Yorston, 2000).
A major advantage of the DDD method is that the DDD
values are published by the WHO and readily and easily acces-
sible for researchers. This enables investigators in different
places to carry out comparisons with valid results.
Finally, the dose calculation methods investigated in this
study are based on averages of doses recommended by
manufacturers and approved by regulatory bodies or on ex-
pert-estimates of approximate clinically equivalent potency
and not on research (Bezchlibnyk-Butler and Jeffries, 2007).
However, a recent article has been published on internationalconsensus on antipsychotic dosing based on opinions of a di-
verse group of international clinical and research experts
(Gardner et al., 2010). In this study, participants (N= 43)
from 18 countries provided dosing recommendations regard-
ing treatment of psychotic disorders for 37 oral agents and
14 short-acting and 10 long-acting parenteral agents. With
olanzapine 20 mg/day as reference, estimated clinical equiva-
lency ratios of oral agents ranged from 0.025 for sulpiride to
10.0 for triﬂuperidol. Seventeen patient and treatment charac-
teristics, including age, hepatic and renal function, illness stage
and severity, sex, and diagnosis, were associated with dosing
modiﬁcations (Gardner et al., 2010).
5. Conclusion
In conclusion, all three methods are reliable and coherent. The
highest coherence was observed with CPZeq versus DDDs. In all
three methods, coherence was strongest when dealing with FGA.
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